NCT06739148 The Enhancement Effect of Low-Level Laser Therapy for Muscle Training with Combined NMES and BFR
| NCT ID | NCT06739148 |
| Status | Recruiting |
| Phase | — |
| Sponsor | National Cheng-Kung University Hospital |
| Condition | Blood Flow Restriction Therapy |
| Study Type | INTERVENTIONAL |
| Enrollment | 44 participants |
| Start Date | 2024-10-01 |
| Primary Completion | 2025-07-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 44 participants in total. It began in 2024-10-01 with a primary completion date of 2025-07-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Blood flow restriction training (BFR) with neuromuscular stimulation (NMES) is employed for individuals with limited mobility and joint issues. However, this approach is highly susceptible to muscle fatigue, despite its potential beneficial effects on muscle strength. Recently, there has been growing interest in using low-level laser therapy (LLLT) to address muscle fatigue. LLLT, known for improving microcirculation and mitochondrial function, shows promise in alleviating enhanced muscle fatigue associated with combined BFR and NMES training. Despite these positive effects, there is limited knowledge about the short-term training impact of combined BFR and NMES with LLLT preconditioning. This project aims to investigate whether the photobiomodulation effects of LLLT could further enhance the training benefits of combined BFR and NMES. The study will employ an integrated analysis of decomposition surface EMG, EEG, and mechanomyogram to explore the behavior and neuromuscular mechanisms underlying the training benefits. If additional benefits are identified, LLLT pre-conditioning is recommended to enhance the use of combined BFR and NMES.
Eligibility Criteria
Inclusion Criteria: 1. Healthy adults aged 20-40, without a diagnosis of cardiovascular or neuromusculoskeletal diseases. 2. Normal vision range after visual correction. Exclusion Criteria: 1. Exclude students who have a teacher-student relationship with the principal investigator to ensure the participants\' autonomy. 2. History of brain injury, stroke, spinal cord injury, or other neuromuscular-related conditions. 3. Contraindications for laser therapy: pregnancy, malignant tumor tissues, bleeding areas, and photosensitive skin regions. 4. Presence of any contraindications for blood flow restriction training, such as a history of injury or strain in the non-dominant arm\'s biceps, deep vein thrombosis or venous occlusion in the non-dominant arm, acute unstable fractures in the non-dominant arm, acute regional infections in the non-dominant arm, severe peripheral arterial occlusive disease in the non-dominant arm, complete lymphatic obstruction in the non-dominant arm, and edema due to acute pulmonary edema or congestive heart failure in the non-dominant arm.
Contact & Investigator
Ing-Shiou Hwang, PhD
STUDY CHAIR
NCKU, Institute of Allied Health Sciences
Frequently Asked Questions
Who can join the NCT06739148 clinical trial?
This trial is open to participants of all sexes, aged 20 Years or older, up to 40 Years, studying Blood Flow Restriction Therapy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06739148 currently recruiting?
Yes, NCT06739148 is actively recruiting participants. Contact the research team at ensureh@gmail.com for enrollment information.
Where is the NCT06739148 trial being conducted?
This trial is being conducted at Tainan, Taiwan.
Who is sponsoring the NCT06739148 clinical trial?
NCT06739148 is sponsored by National Cheng-Kung University Hospital. The principal investigator is Ing-Shiou Hwang, PhD at NCKU, Institute of Allied Health Sciences. The trial plans to enroll 44 participants.